BNO 5.26% 20.0¢ bionomics limited

Ann: End-of-Treatment Milestone Met in Phase 2 PTSD Trial, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 912 Posts.
    lightbulb Created with Sketch. 95
    Treatment complete. I take it that just means the dosing phase of the trial?
    "Topline Data Anticipated to be Reported Late Third Quarter 2018".
    So late September before the headline results are reported.
    I'll mostly be paying attention to the Primary End Point. Even if sub category results are reported they may be indicative only and require more focused future trials.
    Guess we have to wait for the results before we find out the next steps. Potential partners will likely also take a wait and see approach.
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.